Bayer's Pipeline Scores Twice in Three Days, but the Street Is Split on What It's Worth
Published on 10/28/2026 at 16:31 | Editorial boerse-global.de
Two clinical and regulatory wins landed in Bayer's lap within days of each other this week — and the analyst community is still working out whether they add up to a business case or just a pair of promising headlines.
On Monday, Jefferies analyst Michael Leuchten reaffirmed a "Hold" rating and a 46-euro price target on the German drugmaker, calling the efficacy of darolutamide "promising" but framing the data as confirmation of what was already understood rather than a fundamental shift in the story. JPMorgan's Richard Vosser took a sunnier view of the same interim results, keeping an "Overweight" rating and a 61-euro target. Neither house moved its numbers.
What the DASL-HiCaP data actually showed
The interim readout, first presented at the ESMO congress and published by Bayer on Saturday, covered prostate-cancer patients at high risk of recurrence. According to the company, darolutamide on top of standard therapy cut the risk of metastases or death by 58% versus placebo. The four-year metastasis-free survival rate came in at 95%, against 88% in the comparison arm.
Those figures are the reason the study matters: they speak to whether cancer spreads or patients die, not to a single lab value. What they do not yet carry is a label. Darolutamide is not approved for this particular treatment setting, and the data remain an interim analysis — a distinction that separates clinical evidence from commercially usable evidence.
Should investors sell immediately? Or is it worth buying Bayer?
A world-first approval, with a map attached
The regulatory side of the ledger looks different. China's NMPA granted approval to asundexian under the brand name Sunharbo, clearing it for reducing stroke risk in adults after a non-cardioembolic ischemic stroke or a high-risk TIA. Bayer describes it as the first FXIa inhibitor approved anywhere in the world.
Scope matters here. The decision covers China and the specific patient groups named in the label; it does not imply clearance in other jurisdictions or broader use. Nor does a regulatory green light translate into a defined revenue contribution — it creates the precondition for one.
Two different stages, two different kinds of proof
The temptation for investors is to treat the two developments as a single story of momentum. They are not at the same stage. Asundexian has cleared a regulatory hurdle in one market; darolutamide has generated evidence that could, if later results support it, underpin an expansion of its approved use. The first is a permission, the second a possibility.
That gap is where the real risk sits. Pricing a potential additional indication as though it were already booked business skips over the distance between a study result, an approval and an actual sale. Likewise, the "world-first" framing on asundexian describes a regulatory milestone — it says nothing on its own about demand or a fixed commercial outcome.
Bayer at a turning point? This analysis reveals what investors need to know now.
Elsewhere in the group
Bayer's subsidiary AskBio, which operates independently within the conglomerate, said last Thursday it will present five papers on AAV manufacturing technologies at the ESGCT congress, running from 27 to 30 October in Hamburg.
For now, the constructive reading holds as long as investors keep the two tracks separate. The next concrete catalyst would be a regulatory decision on darolutamide in the setting just studied — a positive outcome there would change its status materially compared with today's interim data. Until then, the extra business belongs in the opportunity column, not the guaranteed one.
Ad
Bayer Stock: New Analysis - 28 October
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
